Steritas_Website_HEOR_1267x539pxl_VF4

The cost
of steroid-toxicity
is too high to be ignored

The true costs of steroid-toxicity have yet to be quantified

 

From cataracts to cardiovascular complications, the adverse events associated with long-term use of glucocorticoids are wide-ranging, taking a heavy toll on patients and healthcare systems.
 
Quantifying the economic impact of glucocorticoid-use is a key undertaking to enable value-based care for the millions of patients who suffer from inflammatory conditions, autoimmune diseases and cancer.

Metrics are essential in HEOR studies

 

Health economics outcomes research (HEOR) can help drug developers and healthcare decision-makers gain a better picture of how glucocorticoids and their myriad toxicities influence the value, cost and cost-effectiveness of available treatments. 

 

The STOX® Suite provides HEOR teams with scientifically rigorous assessments that reveal steroid-toxicity in prospective and retrospective studies of large patient populations.

 

The STOX Suite enables accurate measurement of steroid-toxicity. The STOX Suite includes clinical outcome assessments (COA) optimized for different settings:

  • The GTI: calculates change scores across nine health domains in adults
  • The GTI-MD: quantifies change across four metabolic domains in claims and EMR data
  • The pGTI: captures the change scores in nine health domains in children 

 

Bring hidden insights to light with GTI-MD

The Steritas GTI-MD is of particular utility for HEOR, enabling researchers to analyze large claims and electronic health record datasets to understand how glucocorticoid use and cumulative dose are associated with increased steroid-toxicity. This provides a foundation for assessing the benefits of non-steroid alternative treatments.

 

Through quantitative analysis of treatment costs associated with the 80+ known steroid-toxicities, researchers can use GTI-MD for retrospective data analysis to develop a more accurate picture of how glucocorticoids affect patients outside of controlled clinical trials and anecdotal data collected at the point of care.

 

Ultimately, these insights may inform treatment guidelines, payer coverage and help pharmaceutical companies make data-driven decisions about where the greatest medical needs lie when considering the development of new steroid-sparing therapies.

"At a fraction of the time and cost of a phase 3 trial, medical affairs and HEOR teams can now interrogate millions of anonymized records in robust longitudinal datasets, for valuable insights that have been hiding in the dark for years. With the GTI-MD, we can bring insights to light.”

Martha N. Stone

CEO Steritas
 

“We're using the same tools that demonstrate the benefit of our drugs to show that the long-term cost of steroids has been vastly underestimated.”

Glenn Philips, PhD

Vice President of Health Economics and Outcomes Research, Argenx

Learn More
“It is so important to educate payers and providers about the downstream adverse events and long-term costs associated with steroid use.”

Lili Brillstein

Founder and CEO of BCollaborative

Learn More
"By applying the GTI-MD to secondary data, we have conducted reasonably large-sized studies in rare diseases within very short time periods at a fraction of the cost of an observational study."

Albert Whangbo, PhD

Principal, ZS Associates

Health Economics Outcomes Research Panel Discussion

 

During our recent webinar panel discussion,  panellists highlighted that using the GTI-MD in large datasets for HEOR studies delivers:

 

  • The power of a phase 3 trial in just months at a fraction of the cost using readily available data that requires no patient assessment burden
  • A broad opportunity to gain insight into total cost-benefits and the implications of healthcare resource utilization
  • The ability to evaluate the impact of a drug and its ability to reduce steroid-toxicity from real-world data

 

 

Is your HEOR team ready to do more with claims data?

Watch the full on demand webinar today!

Watch now